Go here to learn more or to get a mailed copy.
Home » Clinical Trials
The American Society of Clinical Oncology (ASCO) held its Annual Meeting in Chicago in early June. PCF Young Investigator Eugene Shenderov, MD, of Johns Hopkins, presented early results of a new immunotherapy agent in localized prostate cancer. Patients diagnosed with intermediate- and high-risk prostate cancer have treatment options such as. Read More
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest scientific meetings focused on cancer, where physicians, scientists, advocates, and industry partners share the latest developments in research and treatment. At the 2022 meeting held in Chicago this summer, there were multiple presentations on 177Lutetium-PSMA-617 (Lu-PSMA;. Read More
Prostate cancer can be slow to progress, frustrating the development of new therapies for patients with early, high-risk disease. New results from ICECaP (Intermediate Clinical Endpoints for Cancer of the Prostate), a PCF-supported initiative led by Dr. Christopher Sweeney, will cut the time required to assess new therapies for aggressive. Read More
Investigator: Steve Y. Cho, MD – Assistant Professor, Johns Hopkins University Translation of [18F]DCFBC PET:A Novel Prostate Imaging Biomarker Positron Emission Tomography (PET) is a molecular imaging technique that can produce a 3-D image of human cancers. This system works by injecting a patient with a radionuclide tracer (a compound. Read More
PCF-Department of Defense Prostate Cancer Clinical Trials Consortium (PCCTC) As part of its aggressive plan to fund and accelerate research—and to speed the results to patients worldwide—PCF has invested more than $45 million in a consortium of 13 leading cancer centers, featuring some of the world’s most respected prostate cancer clinical. Read More